Department of Pediatric Hematology-Oncology, Texas Children's Cancer Center, Baylor College of Medicine
With a great interest in human diseases and the mechanisms controlling them, I investigated the role of specific signaling mechanisms that drive cancer stem cell (CSC) driven tumorigenesis and metastasis in pediatric cancer neuroblastoma. As a postdoctoral fellow at Department of Pediatrics, Baylor College of Medicine, I discovered a novel cancer stem cell-like cells marked by G-CSFR (CD114+) in neuroblastoma using in vitro and in vivo models. I further expanded my research to establish the role of G-CSF as a neuroblastoma cancer stem cell specific growth factor. In addition, I successfully collaborated with other researchers and produced several peer-reviewed publications in the area of neuroblastoma cancer biology. During my initial postdoctoral training at INSERM, Paris, France, I was involved in the studies of Transferrin Receptor1 (TfR1) and an anti-TfR antibody as a therapeutic molecule in different human diseases. These studies leads to two major publications in the field. During my doctoral research training at University of Lucknow, India, I developed synthetic human alpha-1-antitrypsin (rhAAT) gene and achieved high-level expression to inexpensively produce bio-similar hAAT for therapeutic purposes. I have developed protein engineered variants of hAAT for increased biological activity and stability. I first authored three research articles, co-authored a research article and a review article describing the findings of my doctoral research.
Cancer Therapy, Solid Tumor, Epigenetics, Cancer stem cell, Pediatrics cancer, Neuroblastoma, Neurooncology, Immunotherapy, STAT3 Pathway, p53, MYCN, Apoptosis, Cell Cycle, Epigenetic inhibitors